Is there a future for 'speculative' gene patents in Europe?

Nat Rev Drug Discov

Mathys & Squire Intellectual Property, 100 Gray's Inn Road, London WC1X 8AL, United Kingdom.

Published: May 2003

In the face of increasing public opposition to patents claiming property in gene sequences, is it right to deny the validity of patent applications that seem to have firm, if somewhat hypothetical, scientific basis? In this article we review the recent state of the law in Europe as it applies to gene patents in order to determine whether there is any hope for the modern heirs of Galilean innovation.

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrd1089DOI Listing

Publication Analysis

Top Keywords

gene patents
8
future 'speculative'
4
'speculative' gene
4
patents europe?
4
europe? face
4
face increasing
4
increasing public
4
public opposition
4
opposition patents
4
patents claiming
4

Similar Publications

Early-stage and metastatic breast cancers (MBC) can exhibit genomic heterogeneity, even within the same individual. Response to therapy in metastatic breast cancer patients with multiple metastases can also be heterogeneous, with different degrees of responsiveness to the same drug(s) across metastatic sites, termed "mixed response," within the same patient. Whether this treatment response variability is influenced by factors such as intrinsic tumor characteristics of metastatic lesions and/or the microenvironment is unknown.

View Article and Find Full Text PDF

Prospective trial of the Oncobox platform RNA sequencing bioinformatic analysis for personalized prescription of targeted drugs.

Comput Biol Med

January 2025

Oncobox Ltd., Moscow, Russia; World-Class Research Center "Digital Biodesign and Personalized Healthcare", Sechenov First Moscow State Medical University, Moscow, Russia; Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, 117997, Russia; PathoBiology Group, European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium. Electronic address:

Interrogating gene expression in tumor can identify up- and downregulated molecular targets of cancer drugs. Here we report the results of prospective clinical investigation of using RNA sequencing analysis for personalized cancer therapy. Transcriptomic profiles were analyzed using Oncobox platform that identifies altered expression of drug target genes and molecular pathways and builds a personalized rating of targeted therapeutics.

View Article and Find Full Text PDF

Research in aging often refers to animal models, particularly C57BL/6J (B6J) mice, considered gold standard. However, B6J mice are distributed by different suppliers, which results in divers substrains exhibiting notable phenotypic differences. To ensure a suitable phenotype of cardiac aging, we performed heart analyses of young (5 months) and old B6J mice (24 months) from two substrains: B6JRj (Janvier) and B6JCrl mice (Charles River).

View Article and Find Full Text PDF

Establishment and application of a zebrafish model of Werner syndrome identifies sapanisertib as a potential antiaging drug.

Proc Natl Acad Sci U S A

February 2025

State Key Laboratory of Genetic Engineering, School of Life Sciences, Liver Cancer Institute of Zhongshan Hospital, Fudan University, Shanghai 200438, China.

Aging is a complex process that affects multiple organs, and the discovery of a pharmacological approach to ameliorate aging is considered the Holy Grail of medicine. Here, we performed an N-ethyl-N-nitrosourea forward genetic screening in zebrafish and identified an accelerated aging mutant named (), harboring a mutation in the - () gene. Loss of leads to a short lifespan and age-related characteristics in the intestine of zebrafish embryos, such as cellular senescence, genomic instability, and epigenetic alteration.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!